REGISTER
Itvisma: One Shot, $2.59M, for SMA
EU approves Novartis' Zolgensma (Itvisma) for SMA patients aged ≥2 years, extending to all ages. Single IV infusion, lifelong SMN1 replacement. Efficacy supported by phase III STEER (HFMSE +2.39 vs +0.51) and STRENGTH (add‑on +1.05). Cost: $2.59M. Prof. Hao Yu notes cure potential but affordability is a barrier without insurance; early treatment, not drug choice, is crucial for preserving function.

A gene therapy priced at $2.59 million received approval in Europe this month for a rare disease that can cause lifelong disability and even premature death.

On July 2, Novartis announced that its AAV gene therapy Itvisma had been approved by the European Commission for the treatment of spinal muscular atrophy (SMA) in patients aged 2 years and older.

As early as 2019, another formulation of this drug – Zolgensma – had already been approved by the U.S. FDA for children under 2 years of age, with a price tag of approximately $2.1 million, setting a record as the world’s most expensive drug at that time. With Itvisma now successively launched in the United States, Japan, and the European Union, this gene therapy has fully covered SMA patients of all ages. It is also understood that the marketing application for Itvisma has been accepted by China’s National Medical Products Administration and has been granted priority review.

This gene therapy is like ‘icing on the cake,’ offering a potential cure for some SMA patients, Prof. Hao Yu from the Department of Medical Genetics/Rare Disease Center, Second Affiliated Hospital of Zhejiang University School of Medicine, told MedJ. However, given its exorbitant price, without adequate insurance or payment mechanisms, its clinical accessibility is not optimistic.

One Treatment, Lifelong Effect

SMA is a common fatal and disabling neuromuscular disease in infants and young children, with an incidence of approximately 1 in 6,000 to 1 in 10,000.

Due to inherited genetic defects, patients have a deletion or mutation of the SMN1 gene on chromosome 5, leading to irreversible degeneration of motor neurons, resulting in progressive and disabling muscle weakness, often accompanied by multi‑system damage including respiratory, digestive, and skeletal systems.

In 2018, SMA was included in China’s first List of Rare Diseases. Statistics show that there are approximately 30,000 SMA patients in China, and it ranks first among fatal genetic diseases in children under 2 years of age. Itvisma, approved this time, is the world’s first gene replacement therapy for SMA patients aged ≥2 years. It uses an adeno‑associated virus (AAV) vector to deliver a healthy SMN1 gene into the patient’s body, enabling cells to continuously produce functional SMN protein.

For this reason, Prof. Yu told MedJ that this therapy requires only a single administration to achieve long‑term efficacy, offering a significant advantage over nusinersen and risdiplam, which require repeated dosing.

It is understood that the approval of Itvisma was based on the pivotal phase III STEER study and the open‑label phase IIIb STRENGTH study. The STEER study showed that in 126 patients with a mean age close to 6 years, Itvisma improved the Hammersmith Functional Motor Scale Expanded (HFMSE) score by 2.39 points, compared with 0.51 points in the placebo group, and the effect lasted at least 52 weeks.

The STRENGTH study further found that in patients who had previously used other therapies and reached a plateau in efficacy, switching to Itvisma led to an additional 1.05‑point increase in HFMSE score.

Prof. Yu told MedJ that, from a clinical evaluation perspective, a 3‑point improvement in HFMSE is generally regarded as the threshold for clinically meaningful significance. Therefore, a 1.05‑point increase does not represent a qualitative leap in motor function.

It is worth emphasizing that for SMA patients whose efficacy has reached a plateau, a further increase in score proves that the introduced SMN gene has been effectively activated and is functioning in the body.

The pathological essence of SMA is progressive and irreversible death of motor neurons. Therefore, already lost motor ability is difficult to reverse substantially. The true value of Itvisma lies in its ability not only to effectively halt disease progression but also to achieve limited but detectable functional improvement – which is exactly the key to its regulatory approval, said Prof. Yu.

A Former Incurable Disease

For a long time, SMA was considered an incurable terminal disease. Prof. Yu told MedJ that in the past, when faced with a confirmed SMA patient, clinicians could only recommend rehabilitation training – improve whatever little can be improved – and had no other options. Our clinical work was mainly limited to diagnosis; the treatment field was completely blank. Patients inevitably progressed to paralysis, and many children did not even live past 2 years.

This situation continued until 2019, when the antisense oligonucleotide drug nusinersen was officially approved in China, and in 2021 it was included in China’s national medical insurance catalog. Also in 2021, the small‑molecule drug risdiplam was launched in China.

This turned an untreatable disease into one that can be effectively intervened, not only directly benefiting patients but also greatly promoting the advancement of the entire SMA diagnosis and treatment system, said Prof. Yu.

Unlike Itvisma, these two drugs target the SMN2 gene, enhancing the efficiency of SMN2 gene production of functional SMN protein to compensate for the deficiency caused by SMN1 gene defects, but they require regular repeated administration.

Itvisma, on the other hand, directly supplements the SMN1 gene in a single dose, truly achieving the potential for single‑dose, long‑term, and even lifelong benefit.

Furthermore, according to Prof. Yu, clinically, some patients reach a plateau in efficacy after a period of SMN2‑targeted therapy.

Prof. Yu said: There is essentially no ‘superiority or inferiority’ between the SMN1 and SMN2 targets, and the potential risk of conflict between the two combined therapies is low. Therefore, the emergence of Itvisma theoretically offers a possibility for synergistic enhancement.

The STRENGTH study preliminarily validated this hypothesis – regardless of whether patients had used other drugs before, the addition of Itvisma still provided a certain degree of additional benefit.

Combination therapy may be a new breakthrough direction in the future. However, there is currently insufficient evidence‑based medicine to confirm the effectiveness of combination regimens and the magnitude of specific patient benefit, said Prof. Yu.

$2.59 million – is It Worth It?

The core advantage of Itvisma is one‑time treatment, but its cost is also huge – $2.59 million.

By comparison, taking nusinersen as an example, it requires an injection every 4 months. After inclusion in the national insurance catalog, the price is about $4,600 (RMB 33,000) per injection, with a patient co‑pay ratio of about 5%–10%.

Prof. Yu told MedJ that the administration of nusinersen requires a certain level of technical skill, and the implementation levels vary significantly across different medical institutions. Experienced physicians can complete the puncture and administration quickly and smoothly. However, some primary healthcare institutions have limited technical capabilities, which may result in multiple puncture failures, significantly increasing patient suffering. Many patients in primary care need to travel regularly to large central hospitals for treatment, and the burden of travel cannot be ignored.

In our center, about 10% of patients are lost to follow‑up due to various reasons and difficulty persisting with treatment, said Prof. Yu.

But this may not be enough to close the huge price gap. Prof. Yu said that from a mechanistic standpoint, Itvisma, as a gene replacement therapy, indeed offers long‑term curative potential that other drugs do not possess. However, it must be acknowledged that there is still a lack of head‑to‑head studies proving that Itvisma has a significant additional efficacy advantage over other therapies. Therefore, even if Itvisma is approved in China in the future, without support from commercial insurance and other multi‑payment mechanisms, relying solely on existing data and the convenience of ‘one shot for life,’ it will hardly achieve real clinical accessibility, said Prof. Yu.

Prof. Yu also reminded that for patients and families, the key to SMA treatment at this stage is not which drug to choose, but whether treatment can be started in a timely manner. The 2025 Expert Consensus on Presymptomatic Treatment of Childhood Spinal Muscular Atrophy clearly states that based on current research evidence, early initiation of disease‑modifying therapy can delay disease onset, especially for children with SMN2 copy number ≥3, where the best achievable state is predicted to be a motor function development timeline and milestones essentially comparable to those of healthy peers.

Clinically, patients who receive timely treatment do have the hope of approaching the motor level of normal peers. But for adult patients who have been ill for many years, motor neurons have already undergone massive irreversible death, and complete recovery is not realistic.

Nevertheless, the value of treatment remains clear – from clinical observations, some patients can achieve mild functional improvement, most can maintain their current status without decline, and a few still progress but at a significantly slower rate. For patients, this is already a tangible benefit.

Having an available drug is only the foundation, said Prof. Yu. Whether through neonatal screening that proactively identifies affected infants, or through early recognition of abnormalities by parents or patients themselves, early intervention is the real key to rewriting the fate of SMA patients. For children, it’s about approaching a normal developmental trajectory; for adults, it determines whether they can maximize preservation of existing function and slow disease progression, said Prof. Yu.

0
0
Loading